Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
A 78-year-old man came to our attention after undergoing coronary computed tomography angiography documenting multivessel coronary artery disease. He was started on treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab 140 mg subcutaneously every 2 weeks. Trea...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2021-08-01
|
| シリーズ: | Medicina |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/1648-9144/57/9/857 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|